CVS Health's first-quarter 2026 results dropped before Wednesday's open and they didn't read like the numbers of a company that opened the year with Wall Street debating whether its insurance business was structurally broken. Total revenue came in at $100.4 billion, up 6.2% year-over-year and the highest quarterly print in the company's history. Adjusted earnings per share hit $2.57 against a Street estimate that had drifted into the low $2.20s in the weeks before the print, as CNBC reported. All three operating segments — Health Care Benefits (Aetna), Health Services (Caremark and the clinic footprint), and Pharmacy & Consumer Wellness (the front-of-store retail business) — beat the Street.
More consequential for the rest of 2026: CVS raised its full-year adjusted EPS guidance to a range of $7.30 to $7.50, up from $7.00 to $7.20, and lifted its revenue floor to at least $405 billion from the prior $400 billion. Cash from operations guidance climbed to at least $9.5 billion. Boring numbers; explosive context. CVS spent most of 2024 and 2025 issuing downward revisions, watching its medical loss ratio creep, and fielding activist pressure to break the conglomerate apart. The stock had already begun pricing a turnaround, per coverage on stocktitan. This print is the validation.
The Aetna story is the one that matters for the broader retail-health complex. Insurance revenue came in at $35.97 billion against $33.28 billion expected. The medical benefit ratio — the percentage of premiums Aetna pays out as claims, the metric that has been the single biggest variable in CVS's stock price for two years — fell to 84.6% from 87.3% a year ago and well below the 86.3% Wall Street had penciled in. Anything below 85% is the threshold investors had been waiting for. CVS hit it on the first quarterly print of 2026.
Inside Aetna, an announcement on prior-authorization reform ran alongside the earnings: Aetna has now standardized data requirements for 88% of prior-authorization volume, approves more than 95% of eligible requests within 24 hours, processes 83% in real time, and has eliminated roughly one million provider phone calls through automation. Those operational metrics translate directly into the medical loss ratio, and they're the kind of structural fix that compounds across quarters rather than reverting next time flu season is bad.
The retail pharmacy story is messier and worth flagging for anyone covering the front end of the business. Pharmacy & Consumer Wellness revenue came in essentially flat at $32.0 billion. Prescriptions ticked up to 451.2 million. But operating income for the unit fell 8.8% year-over-year on regulatory drug-price changes, a milder cold and flu season, and weather disruptions that slowed store operations in February. The Rite Aid acquisition is feeding new prescription volume into CVS pharmacies, but the per-script economics are still compressing under the same reimbursement pressure that pushed Walgreens private last year.
That divergence — Aetna fixing itself faster than the front store can hold margins — is the structural question for CVS's next two years. If the insurance business stays disciplined, the conglomerate model that CVS has spent a decade building genuinely starts to look like a moat: integrated pharmacy benefits, retail dispensing, primary-care clinics, and an insurer with one of the largest provider networks in the country, all under one P&L. If the medical loss ratio drifts back toward 87%, the breakup pressure returns immediately and the pharmacy weakness becomes a second front.
For now, CVS is the only large public company in the pharmacy-retail-insurance triangle running a real raise. Healthcare Dive's coverage of the prior quarter framed CVS as holding 2026 guidance steady as the turnaround plan bears fruit. Three months later, "steady" turned into "raised." Walgreens is private. Rite Aid is being absorbed. The independent pharmacy channel is contracting. CVS has $405 billion of revenue, the largest pharmacy benefit manager in the country, an insurer that just printed an 84.6% MLR, and 9,000 stores. As of Wednesday morning, it also has the burden of proof shifted: the question for analysts on this afternoon's call isn't whether the turnaround is real. It's how durable it is.